Genovis rights issue oversubscribed

The issue was subscribed for about SEK 25.4 million, which it was oversubscribed
by 10 %.
Of the total issue volume of 18,431,387 shares, 93 % were subscribed for with
preferential rights. The rights issue raised about SEK 23 million before issue
expenses for Genovis. Statements of account will be sent on June 13, 2016, to
allot shares subscribed for without preferential rights.
For more information, please contact: Fredrik Olsson, CEO, Genovis AB Tel: 0046
(0)46 -101233 fredrik.olsson@genovis.com (sarah.fredriksson@genovis.com)
ABOUT GENOVIS

Genovis is a global company that offers enzyme products that facilitate
development and quality control of biologics to customers in the pharmaceutical
and medical technology industries. The Company markets several enzyme products
(“SmartEnzymes”) in innovative product formats all over the world.

The organization consists of Genovis AB and the wholly owned subsidiary Genovis
Inc. in the US. Genovis Inc. handles all sales of enzyme products on the North
American market and Genovis AB handles sales in the rest of the world. Genovis
shares are listed on Nasdaq First North Stockholm and Consensus is the Company’s
Certified Adviser, t: +46(0) 31 745 50 00.

This press release is a translation of the Swedish original. In the event of any
discrepancy between this translation and the Swedish original,
the Swedish version shall prevail.